Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model

Sachiko Ohshima-Hosoyama, Monika Davare, Suresh I. Prajapati, Jinu Abraham, Sangeet Lal, Laura D. Nelon, Aoife Kilcoyne, Francis J. Giles, Martha A. Hanes, Brian P. Rubin, Charles Keller

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Overexpression of platelet-derived growth factor receptor alpha (PDGFR-A) has been documented in association with primary tumors and metastasis in medulloblastoma. Tumors from our genetically engineered sonic hedgehog-driven medulloblastoma mouse model overexpress PDGFR-A in primary tumors and thus this mouse model is a good platform with which to study the role of PDGFR-A in this central nervous system malignancy. We hypothesized that inhibition of PDGFR-A in medulloblastoma can slow or inhibit tumor progression in living individuals. To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib (MLN-518), which strongly inhibits PDGFR-A. Although PDGFR-A inhibition by this agent resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360 mg/kg) in vivo. Thus, tandutinib may be an agent of interest for sonic hedgehog-driven medulloblastoma if a synergistic drug combination can be identified.

Original languageEnglish (US)
Pages (from-to)116-121
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume34
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Medulloblastoma
Platelet-Derived Growth Factor alpha Receptor
Transgenic Mice
Neoplasms
Hedgehogs
tandutinib
Drug Combinations
Growth
Tumor Burden
Protein-Tyrosine Kinases
Central Nervous System
Cell Proliferation
Apoptosis
Neoplasm Metastasis

Keywords

  • medulloblastoma
  • platelet-derived growth factor receptor
  • tandutinib
  • virtual histology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Ohshima-Hosoyama, S., Davare, M., Prajapati, S. I., Abraham, J., Lal, S., Nelon, L. D., ... Keller, C. (2012). Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. Journal of Pediatric Hematology/Oncology, 34(2), 116-121. https://doi.org/10.1097/MPH.0b013e3182309fe4

Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. / Ohshima-Hosoyama, Sachiko; Davare, Monika; Prajapati, Suresh I.; Abraham, Jinu; Lal, Sangeet; Nelon, Laura D.; Kilcoyne, Aoife; Giles, Francis J.; Hanes, Martha A.; Rubin, Brian P.; Keller, Charles.

In: Journal of Pediatric Hematology/Oncology, Vol. 34, No. 2, 03.2012, p. 116-121.

Research output: Contribution to journalArticle

Ohshima-Hosoyama, S, Davare, M, Prajapati, SI, Abraham, J, Lal, S, Nelon, LD, Kilcoyne, A, Giles, FJ, Hanes, MA, Rubin, BP & Keller, C 2012, 'Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model', Journal of Pediatric Hematology/Oncology, vol. 34, no. 2, pp. 116-121. https://doi.org/10.1097/MPH.0b013e3182309fe4
Ohshima-Hosoyama, Sachiko ; Davare, Monika ; Prajapati, Suresh I. ; Abraham, Jinu ; Lal, Sangeet ; Nelon, Laura D. ; Kilcoyne, Aoife ; Giles, Francis J. ; Hanes, Martha A. ; Rubin, Brian P. ; Keller, Charles. / Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model. In: Journal of Pediatric Hematology/Oncology. 2012 ; Vol. 34, No. 2. pp. 116-121.
@article{c890b8a425354e90b2183790d8d0ef7a,
title = "Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model",
abstract = "Overexpression of platelet-derived growth factor receptor alpha (PDGFR-A) has been documented in association with primary tumors and metastasis in medulloblastoma. Tumors from our genetically engineered sonic hedgehog-driven medulloblastoma mouse model overexpress PDGFR-A in primary tumors and thus this mouse model is a good platform with which to study the role of PDGFR-A in this central nervous system malignancy. We hypothesized that inhibition of PDGFR-A in medulloblastoma can slow or inhibit tumor progression in living individuals. To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib (MLN-518), which strongly inhibits PDGFR-A. Although PDGFR-A inhibition by this agent resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360 mg/kg) in vivo. Thus, tandutinib may be an agent of interest for sonic hedgehog-driven medulloblastoma if a synergistic drug combination can be identified.",
keywords = "medulloblastoma, platelet-derived growth factor receptor, tandutinib, virtual histology",
author = "Sachiko Ohshima-Hosoyama and Monika Davare and Prajapati, {Suresh I.} and Jinu Abraham and Sangeet Lal and Nelon, {Laura D.} and Aoife Kilcoyne and Giles, {Francis J.} and Hanes, {Martha A.} and Rubin, {Brian P.} and Charles Keller",
year = "2012",
month = "3",
doi = "10.1097/MPH.0b013e3182309fe4",
language = "English (US)",
volume = "34",
pages = "116--121",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model

AU - Ohshima-Hosoyama, Sachiko

AU - Davare, Monika

AU - Prajapati, Suresh I.

AU - Abraham, Jinu

AU - Lal, Sangeet

AU - Nelon, Laura D.

AU - Kilcoyne, Aoife

AU - Giles, Francis J.

AU - Hanes, Martha A.

AU - Rubin, Brian P.

AU - Keller, Charles

PY - 2012/3

Y1 - 2012/3

N2 - Overexpression of platelet-derived growth factor receptor alpha (PDGFR-A) has been documented in association with primary tumors and metastasis in medulloblastoma. Tumors from our genetically engineered sonic hedgehog-driven medulloblastoma mouse model overexpress PDGFR-A in primary tumors and thus this mouse model is a good platform with which to study the role of PDGFR-A in this central nervous system malignancy. We hypothesized that inhibition of PDGFR-A in medulloblastoma can slow or inhibit tumor progression in living individuals. To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib (MLN-518), which strongly inhibits PDGFR-A. Although PDGFR-A inhibition by this agent resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360 mg/kg) in vivo. Thus, tandutinib may be an agent of interest for sonic hedgehog-driven medulloblastoma if a synergistic drug combination can be identified.

AB - Overexpression of platelet-derived growth factor receptor alpha (PDGFR-A) has been documented in association with primary tumors and metastasis in medulloblastoma. Tumors from our genetically engineered sonic hedgehog-driven medulloblastoma mouse model overexpress PDGFR-A in primary tumors and thus this mouse model is a good platform with which to study the role of PDGFR-A in this central nervous system malignancy. We hypothesized that inhibition of PDGFR-A in medulloblastoma can slow or inhibit tumor progression in living individuals. To test our hypothesis, we targeted PDGFR-A mediated tumor growth in vitro and in vivo using the tyrosine kinase inhibitor, tandutinib (MLN-518), which strongly inhibits PDGFR-A. Although PDGFR-A inhibition by this agent resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360 mg/kg) in vivo. Thus, tandutinib may be an agent of interest for sonic hedgehog-driven medulloblastoma if a synergistic drug combination can be identified.

KW - medulloblastoma

KW - platelet-derived growth factor receptor

KW - tandutinib

KW - virtual histology

UR - http://www.scopus.com/inward/record.url?scp=84857921740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857921740&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e3182309fe4

DO - 10.1097/MPH.0b013e3182309fe4

M3 - Article

C2 - 22146535

AN - SCOPUS:84857921740

VL - 34

SP - 116

EP - 121

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -